Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estramustine, Docetaxel, and Exisulind in Hormone Refractory Prostate Cancer
NCT00052845Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Nov 2002
- Primary completion
- Jan 2006
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of exisulind in prostate cancer (PCa), sponsored by Cancer and Leukemia Group B. Started Nov 2002; status: completed.
02
Drugs
exisulind
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00052845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052845.